Reports n Reports has added a new market research report ‘Biosimilars : Market Entry Strategies’ to its store. This report provides an analysis of strategies employed by the top 50 pharma companies that are active or plan to enter the biosimilars sector in the future, together with an analysis of biosimilar deal trends among the top 50 pharma companies.

Of the companies analyzed, each of the eight generic firms ranked among the top pharmaceutical firms with an active interest in Biosimilars. This reflects the fact that such products have the opportunity to increase the profit margin of generic companies. Many innovative pharma companies have also entered this field although some are not inclined to do so and instead, opted to maintain their innovative focus.

Study Comprehensive Table of Contents and Request a Sample for the report @

With sales for the top 50 pharma companies forecast to decline by 1.6% during 2010-16, many leading drugmakers are looking to expand into markets which offer long-term growth, limited competition, and are relatively low risk. Biosimilars is one such area, which has attracted both innovative biologics players and generics players alike.